WBI-4005: Novel Small Molecule Anti-Inflammatory
WBI-4005 is a novel, non-steroidal, anti-inflammatory lead candidate selected from a series of rationally
designed small molecules from our drug discovery program.
The anti-inflammatory activity of the multi-targeted WBI-4005 has been demonstrated in enzymatic
activity assays as well as functional cell based assays. In Vivo studies have further demonstrated WBI-
4005 to be orally bio-available and possess significant efficacy in animal disease models.
In immune cells, WBI-4005 strongly inhibits the production of multiple key inflammatory mediators and
shows activity against multiple cell types including T-cells and macrophages.
WBI-4005 is under pre-clinical development for the treatment of chronic inflammatory diseases that
affect millions of people worldwide.